Page 3 - உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் Today - Breaking & Trending Today

Galapagos NV: Galapagos refocuses pipeline and rightsizes operations


Galapagos NV: Galapagos refocuses pipeline and rightsizes operations
Filgotinib launch in Europe on track
Initiated
unaudited
the
.
These last months, we completed a review of our portfolio and development plans with the goal to select a more risk-balanced pipeline. We decided to retain our focus on novel targets to address unmet medical needs in inflammation, fibrosis, and kidney diseases. We also remain fully committed to the launch of Jyseleca in Europe. Moving forward with confidence, we decided to:
Refocus our clinical pipeline by critically examining its risk profile and breadth;
Cut significant cost in the organization to support this re-sized pipeline development; ....

Region Flamande , United Kingdom , Van Gijsel , Elizabeth Goodwin , Raj Parekh , Bart Filius , Carmen Vroonen , Kyra Obolensky , European Commission , Gilead Sciences Inc , Exchange Commission , Japanese Ministry Of Health , Global Head Of Communications Public Affairs , Corporate Communications , Committee For Medicinal Products Human Use , Standard International , Medicinal Products , Human Use , Belgian Government , Katrine Bosley , Japanese Ministry , Gilead Sciences , Galapago Securities , ஒன்றுபட்டது கிஂக்டம் , எலிசபெத் குட்வின் , ராஜ் பரேக் ,

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos refocuses pipeline and rightsizes operations


.
“These last months, we completed a review of our portfolio and development plans with the goal to select a more risk-balanced pipeline. We decided to retain our focus on novel targets to address unmet medical needs in inflammation, fibrosis, and kidney diseases. We also remain fully committed to the launch of Jyseleca in Europe. Moving forward with confidence, we decided to:
Refocus our clinical pipeline by critically examining its risk profile and breadth;
Cut significant cost in the organization to support this re-sized pipeline development;
Task our business development team to identify and execute on a transformative opportunity.
We believe that our strong cash position, expert teams, and solid scientific foundation position us well for future growth,” said Onno van de Stolpe, CEO of Galapagos. ....

Region Flamande , United States , United Kingdom , Van Gijsel , Elizabeth Goodwin , Raj Parekh , Bart Filius , Carmen Vroonen , Kyra Obolensky , European Commission , Gilead Sciences Inc , Exchange Commission , Japanese Ministry Of Health , Corporate Communications , Global Head Of Communications Public Affairs , Committee For Medicinal Products Human Use , Standard International , Medicinal Products , Human Use , Belgian Government , Katrine Bosley , Japanese Ministry , Gilead Sciences , Galapago Securities , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos creates new subscription right plans


.
On 30 April 2021, the supervisory board of Galapagos approved “Subscription Right Plan 2021 BE”, intended for members of personnel of the company and its Belgian subsidiaries, “Subscription Right Plan 2021 RMV”, intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2021 ROW”, intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 2,736,250 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans.
The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €64.76 (the closing price of the share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). The subscription rights are not transferable. The subscription rights under Subscription Right Plan 2021 BE can in principle not be exercised pr ....

Region Flamande , Bruxelles Capitale , Van Gijsel , Elizabeth Goodwin , Carmen Vroonen , Kyra Obolensky , Global Head Of Communications Public Affairs , Corporate Communications , Bright Plan , Euronext Amsterdam , Subscription Right Plan , Gilead Therapeutics , ப்ரூக்ஸெல்ஸ் தலைநகரம் , எலிசபெத் குட்வின் , உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் , பெருநிறுவன தகவல்தொடர்புகள் , சரி திட்டம் , சந்தா சரி திட்டம் , கிலியட் சிகிச்சை ,

Galapagos NV: Galapagos creates new subscription right plans


Galapagos NV: Galapagos creates new subscription right plans
.
On 30 April 2021, the supervisory board of Galapagos approved Subscription Right Plan 2021 BE , intended for members of personnel of the company and its Belgian subsidiaries, Subscription Right Plan 2021 RMV , intended for the employees of its French subsidiary, Galapagos SASU, and Subscription Right Plan 2021 ROW , intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 2,736,250 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans.
The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €64.76 (the closing price of the share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). The subscription rights are not transferable. The subscription rights under Subscription Ri ....

Region Flamande , Bruxelles Capitale , Van Gijsel , Elizabeth Goodwin , Carmen Vroonen , Kyra Obolensky , Global Head Of Communications Public Affairs , Corporate Communications , Bright Plan , Euronext Amsterdam , Subscription Right Plan , Gilead Therapeutics , ப்ரூக்ஸெல்ஸ் தலைநகரம் , எலிசபெத் குட்வின் , உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் , பெருநிறுவன தகவல்தொடர்புகள் , சரி திட்டம் , சந்தா சரி திட்டம் , கிலியட் சிகிச்சை ,

Galapagos creates new subscription right plans


.
On 30 April 2021, the supervisory board of Galapagos approved Subscription Right Plan 2021 BE , intended for members of personnel of the company and its Belgian subsidiaries, Subscription Right Plan 2021 RMV , intended for the employees of its French subsidiary, Galapagos SASU, and Subscription Right Plan 2021 ROW , intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 2,736,250 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans.
The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €64.76 (the closing price of the share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). The subscription rights are not transferable. The subscription rights under Subscription Right Plan 2021 BE can in principle not be exercised prior to 1 Jan ....

Region Flamande , Bruxelles Capitale , Van Gijsel , Elizabeth Goodwin , Carmen Vroonen , Kyra Obolensky , Global Head Of Communications Public Affairs , Corporate Communications , Bright Plan , Euronext Amsterdam , Subscription Right Plan , Gilead Therapeutics , ப்ரூக்ஸெல்ஸ் தலைநகரம் , எலிசபெத் குட்வின் , உலகளாவிய தலை ஆஃப் தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் , பெருநிறுவன தகவல்தொடர்புகள் , சரி திட்டம் , சந்தா சரி திட்டம் , கிலியட் சிகிச்சை ,